Wiki Article
Lu AF28996
Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net
| Clinical data | |
|---|---|
| Other names | Lu-AF28996; LuAF28996; Lu-AF-28996 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine receptor agonist; Dopamine D1 and D2 receptor agonist |
Lu AF28996 is a dual dopamine D1 and D2 receptor agonist which is under development for the treatment of Parkinson's disease.[1][2][3][4][5][6] It is taken orally.[1] Lu AF28996 was first described in the scientific literature by 2021.[3] It is under development by Lundbeck.[1][2] As of April 2025, the drug is in phase 1 clinical trials.[1][2] The chemical structure of Lu AF28996 does not yet appear to have been disclosed.[1]
See also
[edit]References
[edit]- ^ a b c d e f "Lu AF 28996". AdisInsight. 28 April 2025. Retrieved 28 January 2026.
- ^ a b c "Delving into the Latest Updates on Lu-AF28996 with Synapse". Synapse. 3 December 2025. Retrieved 28 January 2026.
- ^ a b McFarthing K, Rafaloff G, Baptista MA, Wyse RK, Stott SR (2021). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update". J Parkinsons Dis. 11 (3): 891–903. doi:10.3233/JPD-219006. PMID 34151864.
- ^ Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S (2023). "Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment". Clin Park Relat Disord. 9: 100212. doi:10.1016/j.prdoa.2023.100212. PMID 37497384.
{{cite journal}}: CS1 maint: article number as page number (link) - ^ McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, Beissert K, Pilcicka A, Fuest R, Wyse RK, Stott SR (2024). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update". J Parkinsons Dis. 14 (5): 899–912. doi:10.3233/JPD-240272. PMID 39031388.
- ^ Gros P, Garcia LA, Fox SH (May 2025). "Experimental Therapeutics in Parkinson's Disease: A Review". Neurol Clin. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID 40185528.